Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
Laure Gossec, Josef S Smolen, Sofía Ramiro, et al.
Annals of the Rheumatic Diseases (2015) Vol. 75, Iss. 3, pp. 499-510
Open Access | Times Cited: 885

Showing 1-25 of 885 citing articles:

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Désirée van der Heijde, Sofía Ramiro, Robert Landewé, et al.
Annals of the Rheumatic Diseases (2017) Vol. 76, Iss. 6, pp. 978-991
Open Access | Times Cited: 1450
Psoriatic Arthritis
Christopher T. Ritchlin, Robert A. Colbert, Dafna D. Gladman
New England Journal of Medicine (2017) Vol. 376, Iss. 10, pp. 957-970
Closed Access | Times Cited: 1095
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 700.1-712
Open Access | Times Cited: 834
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
Victoria Furer, Christien Rondaan, Marloes W Heijstek, et al.
Annals of the Rheumatic Diseases (2019) Vol. 79, Iss. 1, pp. 39-52
Open Access | Times Cited: 660
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Josef S Smolen, Monika Schöls, J. Braun, et al.
Annals of the Rheumatic Diseases (2017) Vol. 77, Iss. 1, pp. 3-17
Open Access | Times Cited: 616
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
Philip J. Mease, Stephen Hall, Oliver FitzGerald, et al.
New England Journal of Medicine (2017) Vol. 377, Iss. 16, pp. 1537-1550
Open Access | Times Cited: 511
2016 update of the EULAR recommendations for the management of early arthritis
Bernard Combe, Robert Landewé, C. Daïen, et al.
Annals of the Rheumatic Diseases (2017) Vol. 76, Iss. 6, pp. 948-959
Open Access | Times Cited: 509
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Dafna D. Gladman, William F. C. Rigby, Valdeŕilio Feijó Azevedo, et al.
New England Journal of Medicine (2017) Vol. 377, Iss. 16, pp. 1525-1536
Open Access | Times Cited: 470
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial
Laura C. Coates, Anna R. Moverley, Lucy McParland, et al.
The Lancet (2015) Vol. 386, Iss. 10012, pp. 2489-2498
Open Access | Times Cited: 446
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, et al.
Arthritis Care & Research (2018) Vol. 71, Iss. 1, pp. 2-29
Open Access | Times Cited: 438
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
Josef S Smolen, J. Braun, Maxime Dougados, et al.
Annals of the Rheumatic Diseases (2013) Vol. 73, Iss. 1, pp. 6-16
Open Access | Times Cited: 431
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
Arthur Kavanaugh, Philip J. Mease, Juan J. Gómez‐Reino, et al.
Annals of the Rheumatic Diseases (2014) Vol. 73, Iss. 6, pp. 1020-1026
Open Access | Times Cited: 425
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, et al.
Arthritis & Rheumatology (2018) Vol. 71, Iss. 1, pp. 5-32
Open Access | Times Cited: 401
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash, Bruce Kirkham, Masato Okada, et al.
The Lancet (2017) Vol. 389, Iss. 10086, pp. 2317-2327
Closed Access | Times Cited: 357
EULAR recommendations for the health professional’s approach to pain management in inflammatory arthritis and osteoarthritis
Rinie Geenen, Cécile L Overman, Robin Christensen, et al.
Annals of the Rheumatic Diseases (2018), pp. annrheumdis-212662
Open Access | Times Cited: 310
Psoriatic arthritis: state of the art review
Laura C. Coates, Philip Helliwell
Clinical Medicine (2017) Vol. 17, Iss. 1, pp. 65-70
Open Access | Times Cited: 273
2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative
Christian Dejaco, Yogesh Preet Singh, Pablo Perel, et al.
Arthritis & Rheumatology (2015) Vol. 67, Iss. 10, pp. 2569-2580
Open Access | Times Cited: 271
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
Philip J. Mease, Désirée van der Heijde, Robert Landewé, et al.
Annals of the Rheumatic Diseases (2018), pp. annrheumdis-212687
Open Access | Times Cited: 252
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Philip J. Mease, Josef S Smolen, Frank Behrens, et al.
Annals of the Rheumatic Diseases (2019) Vol. 79, Iss. 1, pp. 123-131
Open Access | Times Cited: 249
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
Iain B. McInnes, Frank Behrens, Philip J. Mease, et al.
The Lancet (2020) Vol. 395, Iss. 10235, pp. 1496-1505
Closed Access | Times Cited: 237
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Peter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 1, pp. 71-87
Open Access | Times Cited: 235
International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials
Ana‐Maria Orbai, Maarten de Wit, Philip J. Mease, et al.
Annals of the Rheumatic Diseases (2016) Vol. 76, Iss. 4, pp. 673-680
Open Access | Times Cited: 229
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis
Andrew D. Dick, James T. Rosenbaum, Hassan Al-Dhibi, et al.
Ophthalmology (2018) Vol. 125, Iss. 5, pp. 757-773
Open Access | Times Cited: 214
Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative
P Bálint, Lene Terslev, Philippe Aegerter, et al.
Annals of the Rheumatic Diseases (2018) Vol. 77, Iss. 12, pp. 1730-1735
Closed Access | Times Cited: 211
Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial
Philip J. Mease, Dafna D. Gladman, David H. Collier, et al.
Arthritis & Rheumatology (2019) Vol. 71, Iss. 7, pp. 1112-1124
Open Access | Times Cited: 191
Page 1 - Next Page

Scroll to top